In conclusion, we present evidence in the present study that CTSO is a new factor of importance for tamoxifen efficacy as a chemopreventive agent in women at high risk of developing breast cancer as well as evidence for a potential mechanism by which this effect involves BRCA1. This evidence concerns the gene BRCA1 and breast carcinoma.